Townsend Richard Nolan sold 3,345 shares of Lexeo Therapeutics, Inc. at $4.95 for −$16.6k on Aug 18, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Executive Officer
Chief Executive Officer
Filed Aug 19, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$16,561.76Shares × reported price
Shares traded
3,345Common Stock
Price per share
$4.95Reported price. Read footnotes for ranges.
% of reported position traded
0.89%This security and ownership context
Holdings after
374,472Direct
Trade date
Aug 18, 2026Sell
Filed
Aug 19, 2026, 5:00 PM ET1-day reporting delay
Accession
0001995218-26-000015Code S · Transaction 11481
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 377,817 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

LXEO price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
LXEO · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −13%1w ago −11%1d ago −7.3%
Returns since7d −6.7%30d −22%90d180d1y

Footnotes in full

F1: Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs"). F2: This transaction was executed in multiple trades at prices ranging from $4.83 to $5.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3: Includes 242,911 Restricted Stock Units.